Skip to content

A Study Comparing Laparoscopic/Robotic Stoma Reduced-Port Fusion Surgery with Traditional Surgery in Patients with Temporary Ileostomy

A Prospective, Randomized, Parallel-Controlled Study Comparing Laparoscopic/Robotic Stoma Reduced-Port Fusion Surgery with Traditional Surgery in Patients with Temporary Ileostomy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06604052
Acronym
FUSION
Enrollment
80
Registered
2024-09-19
Start date
2024-09-06
Completion date
2025-12-31
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ileostomy

Keywords

ileostomy, minimally invasive surgery, Reduced-Port Fusion Surgery, stoma complication

Brief summary

The traditional positioning and surgical methods for temporary ileostomy no longer meet the requirements of minimally invasive surgery: (1) Conventional stoma positioning often leads to the trocar incision being too close to the stoma site, increasing the risk of baseplate leakage and skin infection. (2) Since stoma positioning is required to be within the rectus abdominis, the proximity between the stoma and auxiliary incision can heighten difficulties in stoma bag attachment and raises the risk of fecal leakage. (3) Stoma retraction surgery within the rectus abdominis is more traumatic and complex. We introduce for the first time a modified stoma positioning and surgical method, termed Reduced-Port Fusion Surgery. This technique includes preoperative trocar/stoma fusion positioning and intraoperative trocar/stoma fusion surgery. The procedure is based on the 3R principles: Reposition - the stoma is repositioned within the Joint Trocar/Stoma Zone, allowing for more lateral placement to meet surgical needs without being confined to the rectus abdominis. Reduce Port - the same fusion point is used for both trocar insertion and stoma creation, enabling dual use of one site. Recognize - surgeons participate in stoma positioning, recognize the positioning, and follow the procedure. This prospective, randomized, parallel-controlled clinical study aims to evaluate whether Reduced-Port Fusion Surgery can reduce stoma-related complications, postoperative pain, improve quality of life, and facilitate stoma retraction surgery compared to traditional methods. A total of 80 participants will be randomly assigned in a 1:1 ratio. The experimental group will undergo Reduced-Port Fusion Surgery while the control group will receive traditional surgery.

Interventions

PROCEDUREReduced-Port Fusion Surgery

(1) The Joint Trocar/Stoma Zone will be delineated by the stoma therapist. (2) The placement of the fusion point will involve collaboration between the surgeon and stoma therapist. This will be based on the surgeon's trocar placement plan and the stoma therapist's positioning principles. (3) Follow the principles of modified stomal positioning. (4) The surgeon will insert the main trocar based on the preoperative positioning point. During stoma creation, the 12 mm main trocar incision will be extended to 25-30 mm to create an ileostomy.

(1) The stoma therapists perform stoma positioning using traditional stoma positioning method. The surgeon will determine the primary trocar location, ensuring it does not overlap with the stoma site. (2) The surgeon will insert the primary trocar based on the preoperative positioning point and conduct the surgery. During stoma creation, the surgeons create ileal stoma according to the preoperative stoma positioning point.

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. After preoperative evaluation, patients scheduled for laparoscopic/robotic colorectal surgery (rectum, sigmoid colon, left colon) who are planned to undergo prophylactic ileostomy. 2. No serious systemic infection or immunosuppression. 3. Over 18 years of age. 4. Eastern Cooperative Oncology Group Performance Status: 0-1 5. The expected survival time \> 6 months. 6. The subjects voluntarily participate and sign the informed consent

Exclusion criteria

1. Any skin infectious diseases in the abdominal wall. 2. Use hormones and immunosuppressive drugs within 1 month before surgery. 3. The time between operation and the last chemotherapy was less than 1 month. 4. Any previous ostomy surgery. 5. Any serious active infection or uncontrollable infection that requires systematic treatment. 6. A clear history of neurological or psychiatric disorders. 7. Subjects may not be able to complete the study for other reasons.

Design outcomes

Primary

MeasureTime frameDescription
Overall complication rate of stoma7, 30, and 90 days after surgeryObserve and assess for stoma complications

Secondary

MeasureTime frameDescription
Stomal skin infection rate7, 30, and 90 days after surgeryObserve and assess for stomal skin infection rate
Parastostomy trocar incision infection rate7, 30, and 90 days after surgeryTo observe whether trocar incision infection occurred
DET(Discoloration,Erosion and Tissue overgrowth) score7, 30, and 90 days after surgeryMeasure the state of the skin around the stoma and the corresponding lesion area, ranging from 0-15, higher scores mean a worse outcome of stoma
Stoma Pain Score7, 30, and 90 days after surgeryMeasurement of stoma pain level using numerical rating scale,ranging from 0-10, higher scores mean a worse outcome of pain
Quality of life scale score30 and 90 days after surgeryMeasurement of quality of life for patients using the European Organization for Reasearch and Treatment of Cancer QLQ-C30 Questionnaire (EORTC QLQ-C30), ranging from 0-100, higher scores mean a better outcome of quality of life
Parastomal hernia rate7, 30, and 90 days after surgeryTo observe whether parastomal hernia occurred

Countries

China

Contacts

Primary ContactTingyu Wu, PhD
wutingyu@xinhuamed.com.cnChina: +86-021-25077855

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026